Tumor Response Evaluation after Treatment and Post-treatment Surveillance of Hepatocellular Carcinoma
Journal of Liver Cancer
;
: 9-16, 2018.
Article
in Korean
| WPRIM
| ID: wpr-765685
ABSTRACT
Hepatocellular carcinoma is one of the most prevalent malignancies and frequent causes of death worldwide. Treatment options of hepatocellular carcinoma consist of locoregional therapy, surgical resection, liver transplantation, and systemic therapy. Assessment of tumor response is required in patients receiving locoregional and systemic therapy. The Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 is widely used tumor response evaluation criteria. However, the RECIST does not reflect the extent of tumor necrosis after some locoregional therapies and molecular targeted agents. The Modified RECIST (mRECIST), which has the concept of viable tumor, was introduced in order to overcome this problem. The mRECIST were developed on the basis of RECIST version 1.1 and only tumoral tissue showing contrast uptake in arterial phase of dynamic radiologic imaging techniques was measured to assess tumor response. Recently, immune checkpoint inhibitors have emerged as a promising therapeutic modality for the treatment of hepatocellular carcinoma. To identify tumor response after immunotherapy, immune RECIST (iRECIST) has been proposed as consensusbased criteria. After achieving complete response after curative treatment, optimal surveillance was needed to detect recurrence. Individualized surveillance schedule should be considered, taking into consideration the risk factors of the patient and the risk associated with the treatment modalities.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Appointments and Schedules
/
Prognosis
/
Recurrence
/
Radiography
/
Risk Factors
/
Cause of Death
/
Liver Transplantation
/
Carcinoma, Hepatocellular
/
Response Evaluation Criteria in Solid Tumors
/
Immunotherapy
Type of study:
Diagnostic study
/
Etiology study
/
Prognostic study
/
Risk factors
/
Screening study
Limits:
Humans
Language:
Korean
Journal:
Journal of Liver Cancer
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS